ImmunoGen Inc (IMGN)

[skitahoe]

Tomorrow is IMGN's Annual Meeting. I don't know if anything major will be announced there, but I certainly hope further guidance will be provided on how they're proceeding with IMGN853, and perhaps if under confidentiality agreements discussions are underway for a ROW partnership for the drug which previously had been discussed by the company. I'm uncertain if IMGN wants all of North America for itself, or just the U.S., but it's been clear that the ROW is open to a partnership.

I believe that IMGN is dramatically undervalued and as more information is released on a few different products that they, and their partners are working on, the price will rise to at least low double digits by the end of the year, or early next year. That said, I found the January $4 calls to attractive to pass up. If I'm right, I'll sell a small fraction of what I've bought to pay for purchasing all the rest as I've promised my wife I wouldn't use more cash to purchase more IMGN.

Gary